Acuren Corp美国招股说明书（2025年4月24日版）

Up to 5,691,219 Shares of Common Stock This prospectus supplement amends the prospectus dated April 4, 2025 (the “Prospectus”) of Acuren Corporation, a Delawarecorporation (the “Company”), that relates to up to (i) 1,000,000 shares of our common stock issuable upon conversion of ouroutstanding Series A Preferred Stock, which are convertible into common stock on a one-for-one basis, (ii) 4,566,219 shares of ourcommon stock issuable upon exercise of our outstanding warrants, with each warrant exercisable for one-fourth of a share of commonstock at an exercise price of $11.50 per whole share of common stock until July 30, 2027, and (iii) 125,000 shares of our common This prospectus supplement is being filed to update and supplement the information included in the Prospectus with theinformation contained in the Company’s Current Report on Form 8-K filed with the SEC on April 24, 2025, as set forth below. Thisprospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement. Shares of common stock of the Company trade on the NYSE American under the symbol “TIC” and the Company’s warrantshave qualified to trade on the OTCQB Market and are expected to begin trading under the symbol “TICAW” on April 25, 2025. On Investing in the Company’s common stock involves risks. See “Risk Factors” beginning on page 6 of the Prospectus andunder similar headings in any amendments or supplements to the Prospectus. Neither the SEC nor any other regulatory body has approved or disapproved of these securities or passed upon theadequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. The date of this Prospectus Supplement No. 2 is April 24, 2025 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of theregistrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 8.01.Other Events Acuren Corporation (the “Company” or “Acuren”) (NYSE American: TIC) announces that its outstanding warrants that wereissued in connection with the original investment vehicle (the “Warrants”) have qualified to trade on the OTCQB Market. The The Company also announces that, effective as of April 23, 2025, its Warrants are eligible for movement into participantaccounts at the Depository Trust & Clearing Corporation (“DTC”). The CUSIP number for the Company’s Warrants is 00510N110. Holders of the Company’s Warrants currently held as depositary interests through the CREST system operated by Euroclear UK& International Limited (“CREST”) may now transfer such warrants from a CREST participant account in the UK to a DTCparticipant account in the US by contacting their broker or other custodian to request a movement of their position from a CRESTparticipant account into a DTC participant account. CREST participants may contact the Global Transactions team at Computershare, Forward-Looking Statements In this Form 8-K, the Company may discuss events or results that have not yet occurred or been realized, commonly referred toas forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-lookingstatements made by or on behalf of the Company. Such statements relate in this Form 8-K, without limitation, to statements, beliefs,projections and expectations about future events, including the Company’s expectations regarding the commencement of trading onthe OTCQB Market. These statements are not guarantees of future performance and are subject to known and unknown risks,uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to besigned on its behalf by the undersigned hereunto duly authorized. By:/s/ Kristin SchultesName:Kristin SchultesTitle:Chief Financial Officer Date: April 24, 2025